Official Title

Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    methylprednisolone ...
  • Study Participants

    42
Systemic Pulse Glucocorticoids have been shown to be effective in widespread Alopecia areata but not the totalis, universalis or ophiasic type. Whether the failure is due to inadequate dosing, inadequate frequency or other factors is a matter of debate. The investigators decided to conduct this study using the oral pulse steroid, however with higher doses and more frequent pulses to patients with severe forms of Alopecia areata.
This will be a single-center, prospective, randomized study conducted in King Khalid University Hospital. Patients diagnosed with either Alopecia universalis, Alopecia totalis or Ophiasic alopecia will be included in the study. Patients with contraindications such as diabetes mellitus, peptic ulcer, hypertension, infection, psychosis, heart or kidney disease, endocrine disorders (apart from a subclinical hypothyroidism and autoimmune thyroiditis) will be excluded. Children less than 5 years of age and those who received systemic or topical treatment within the last 4 weeks before enrollment will be also excluded. Those of child bearing potential had to have a negative urine pregnancy test result at baseline visit and should practice a reliable method of contraception throughout the study. 42 eligible patients will be randomly assigned to one of 3 treatment groups. Enrolled patients must provide written informed consent. Institutional review board approval will be obtained.
Study Started
Jan 31
2003
Primary Completion
Dec 31
2009
Study Completion
Jul 31
2010
Last Update
Jul 22
2010
Estimate

Drug methylprednisolone sodium succinate

Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

Drug methylprednisolone sodium succinate

Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

Drug methylprednisolone sodium succinate

Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

Group A Experimental

will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks

Group B Active Comparator

will receive 2 consecutive daily pulses every 3 weeks for 24 weeks

Group C Active Comparator

will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.

Criteria

Inclusion Criteria:

Alopecia Universalis
Alopecia Totalis
Ophiasic Alopecia

Exclusion Criteria:

diabetes mellitus
peptic ulcer
hypertension
infection
psychosis
heart disease
kidney disease
endocrine disorders (apart from a subclinical hypothyroidism and autoimmune thyroiditis)
received systemic or topical treatment within the last 4 weeks before enrollment
pregnancy
No Results Posted